- Home
- TOP vs PRLD Comparison
TOP vs PRLD Comparison
Compare TOP & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TOP
- PRLD
- Stock Information
- Founded
- TOP 2015
- PRLD 2016
- Country
- TOP Hong Kong
- PRLD United States
- Employees
- TOP N/A
- PRLD N/A
- Industry
- TOP Investment Bankers/Brokers/Service
- PRLD Medicinal Chemicals and Botanical Products
- Sector
- TOP Finance
- PRLD Health Care
- Exchange
- TOP Nasdaq
- PRLD Nasdaq
- Market Cap
- TOP 62.9M
- PRLD 63.3M
- IPO Year
- TOP 2022
- PRLD 2020
- Fundamental
- Price
- TOP $1.61
- PRLD $1.04
- Analyst Decision
- TOP
- PRLD Buy
- Analyst Count
- TOP 0
- PRLD 3
- Target Price
- TOP N/A
- PRLD $5.33
- AVG Volume (30 Days)
- TOP 142.9K
- PRLD 408.0K
- Earning Date
- TOP 11-26-2024
- PRLD 11-06-2024
- Dividend Yield
- TOP N/A
- PRLD N/A
- EPS Growth
- TOP N/A
- PRLD N/A
- EPS
- TOP 0.03
- PRLD N/A
- Revenue
- TOP $8,037,105.00
- PRLD $3,000,000.00
- Revenue This Year
- TOP N/A
- PRLD N/A
- Revenue Next Year
- TOP N/A
- PRLD N/A
- P/E Ratio
- TOP $49.42
- PRLD N/A
- Revenue Growth
- TOP N/A
- PRLD N/A
- 52 Week Low
- TOP $1.39
- PRLD $1.00
- 52 Week High
- TOP $7.77
- PRLD $6.80
- Technical
- Relative Strength Index (RSI)
- TOP 40.87
- PRLD 21.69
- Support Level
- TOP $1.62
- PRLD $1.14
- Resistance Level
- TOP $1.84
- PRLD $1.36
- Average True Range (ATR)
- TOP 0.10
- PRLD 0.11
- MACD
- TOP -0.00
- PRLD 0.03
- Stochastic Oscillator
- TOP 10.20
- PRLD 7.53
About TOP TOP Financial Group Limited
TOP Financial Group Ltd is an online brokerage firm in Hong Kong specializing in trading local and overseas equities, futures, and options products. The Company generates brokerage commission income by enabling its customers to trade on multiple exchanges present globally. The company operates in only one segment which is the futures brokerage service.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.